Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review

Research output: Contribution to journalReview article

Abstract

Background: Non-Small Cell Lung Cancer (NSCLC) is characterized by aggressiveness and includes the majority of thorax malignancies. The possibility of early stratification of patients as responsive and non-responsive to radiotherapy with a non-invasive method is extremely appealing. The distribution of the Fluorodeoxyglucose (18F–FDG) in tumours, provided by Positron-Emission-Tomography (PET) images, has been proved to be useful to assess the initial staging of the disease, recurrence, and response to chemotherapy and chemo-radiotherapy (CRT). Objectives: In the last years, particular efforts have been focused on the possibility of using ad interim 18F–FDG PET (FDGint) to evaluate response already in the course of radiotherapy. However, controversial findings have been reported for various malignancies, although several results would support the use of FDGint for individual therapeutic decisions, at least in some pathologies. The objective of the present review is to assemble comprehensively the literature concerning NSCLC, to evaluate where and whether FDGint may offer predictive potential. Methods: Several searches were completed on Medline and the Embase database, combining different keywords. Original papers published in the English language from 2005 to 2016 with studies involving FDGint in patients affected by NSCLC and treated with radiation therapy or chemo-radiotherapy only were chosen. Results: Twenty-one studies out of 970 in Pubmed and 1256 in Embase were selected, reporting on 627 patients. Conclusion: Certainly, the lack of univocal PET parameters was identified as a major drawback, while standardization would be required for best practice. In any case, all these papers denoted FDGint as promising and a challenging examination for early assessment of outcomes during CRT, sustaining its predictivity in lung cancer.

Original languageEnglish
Pages (from-to)1915-1927
Number of pages13
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume44
Issue number11
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Fluorodeoxyglucose F18
Non-Small Cell Lung Carcinoma
Positron-Emission Tomography
Radiotherapy
Neoplasms
Practice Guidelines
PubMed
Lung Neoplasms
Language
Thorax
Outcome Assessment (Health Care)
Databases
Pathology
Recurrence
Drug Therapy

Keywords

  • Ad-interim FDG-PET
  • Adaptive radiotherapy
  • Chemo-radiotherapy
  • Lung cancer
  • Non-Small Cell Lung Cancer
  • Tumour response

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{e6bb15aef36a452a87a8f69ebd05bf9c,
title = "Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review",
abstract = "Background: Non-Small Cell Lung Cancer (NSCLC) is characterized by aggressiveness and includes the majority of thorax malignancies. The possibility of early stratification of patients as responsive and non-responsive to radiotherapy with a non-invasive method is extremely appealing. The distribution of the Fluorodeoxyglucose (18F–FDG) in tumours, provided by Positron-Emission-Tomography (PET) images, has been proved to be useful to assess the initial staging of the disease, recurrence, and response to chemotherapy and chemo-radiotherapy (CRT). Objectives: In the last years, particular efforts have been focused on the possibility of using ad interim 18F–FDG PET (FDGint) to evaluate response already in the course of radiotherapy. However, controversial findings have been reported for various malignancies, although several results would support the use of FDGint for individual therapeutic decisions, at least in some pathologies. The objective of the present review is to assemble comprehensively the literature concerning NSCLC, to evaluate where and whether FDGint may offer predictive potential. Methods: Several searches were completed on Medline and the Embase database, combining different keywords. Original papers published in the English language from 2005 to 2016 with studies involving FDGint in patients affected by NSCLC and treated with radiation therapy or chemo-radiotherapy only were chosen. Results: Twenty-one studies out of 970 in Pubmed and 1256 in Embase were selected, reporting on 627 patients. Conclusion: Certainly, the lack of univocal PET parameters was identified as a major drawback, while standardization would be required for best practice. In any case, all these papers denoted FDGint as promising and a challenging examination for early assessment of outcomes during CRT, sustaining its predictivity in lung cancer.",
keywords = "Ad-interim FDG-PET, Adaptive radiotherapy, Chemo-radiotherapy, Lung cancer, Non-Small Cell Lung Cancer, Tumour response",
author = "Marta Cremonesi and Laura Gilardi and Ferrari, {Mahila Esmeralda} and Gaia Piperno and Travaini, {Laura Lavinia} and Robert Timmerman and Francesca Botta and Guido Baroni and Grana, {Chiara Maria} and Sara Ronchi and Delia Ciardo and Jereczek-Fossa, {Barbara Alicja} and Cristina Garibaldi and Roberto Orecchia",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s00259-017-3762-9",
language = "English",
volume = "44",
pages = "1915--1927",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "11",

}

TY - JOUR

T1 - Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review

AU - Cremonesi, Marta

AU - Gilardi, Laura

AU - Ferrari, Mahila Esmeralda

AU - Piperno, Gaia

AU - Travaini, Laura Lavinia

AU - Timmerman, Robert

AU - Botta, Francesca

AU - Baroni, Guido

AU - Grana, Chiara Maria

AU - Ronchi, Sara

AU - Ciardo, Delia

AU - Jereczek-Fossa, Barbara Alicja

AU - Garibaldi, Cristina

AU - Orecchia, Roberto

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: Non-Small Cell Lung Cancer (NSCLC) is characterized by aggressiveness and includes the majority of thorax malignancies. The possibility of early stratification of patients as responsive and non-responsive to radiotherapy with a non-invasive method is extremely appealing. The distribution of the Fluorodeoxyglucose (18F–FDG) in tumours, provided by Positron-Emission-Tomography (PET) images, has been proved to be useful to assess the initial staging of the disease, recurrence, and response to chemotherapy and chemo-radiotherapy (CRT). Objectives: In the last years, particular efforts have been focused on the possibility of using ad interim 18F–FDG PET (FDGint) to evaluate response already in the course of radiotherapy. However, controversial findings have been reported for various malignancies, although several results would support the use of FDGint for individual therapeutic decisions, at least in some pathologies. The objective of the present review is to assemble comprehensively the literature concerning NSCLC, to evaluate where and whether FDGint may offer predictive potential. Methods: Several searches were completed on Medline and the Embase database, combining different keywords. Original papers published in the English language from 2005 to 2016 with studies involving FDGint in patients affected by NSCLC and treated with radiation therapy or chemo-radiotherapy only were chosen. Results: Twenty-one studies out of 970 in Pubmed and 1256 in Embase were selected, reporting on 627 patients. Conclusion: Certainly, the lack of univocal PET parameters was identified as a major drawback, while standardization would be required for best practice. In any case, all these papers denoted FDGint as promising and a challenging examination for early assessment of outcomes during CRT, sustaining its predictivity in lung cancer.

AB - Background: Non-Small Cell Lung Cancer (NSCLC) is characterized by aggressiveness and includes the majority of thorax malignancies. The possibility of early stratification of patients as responsive and non-responsive to radiotherapy with a non-invasive method is extremely appealing. The distribution of the Fluorodeoxyglucose (18F–FDG) in tumours, provided by Positron-Emission-Tomography (PET) images, has been proved to be useful to assess the initial staging of the disease, recurrence, and response to chemotherapy and chemo-radiotherapy (CRT). Objectives: In the last years, particular efforts have been focused on the possibility of using ad interim 18F–FDG PET (FDGint) to evaluate response already in the course of radiotherapy. However, controversial findings have been reported for various malignancies, although several results would support the use of FDGint for individual therapeutic decisions, at least in some pathologies. The objective of the present review is to assemble comprehensively the literature concerning NSCLC, to evaluate where and whether FDGint may offer predictive potential. Methods: Several searches were completed on Medline and the Embase database, combining different keywords. Original papers published in the English language from 2005 to 2016 with studies involving FDGint in patients affected by NSCLC and treated with radiation therapy or chemo-radiotherapy only were chosen. Results: Twenty-one studies out of 970 in Pubmed and 1256 in Embase were selected, reporting on 627 patients. Conclusion: Certainly, the lack of univocal PET parameters was identified as a major drawback, while standardization would be required for best practice. In any case, all these papers denoted FDGint as promising and a challenging examination for early assessment of outcomes during CRT, sustaining its predictivity in lung cancer.

KW - Ad-interim FDG-PET

KW - Adaptive radiotherapy

KW - Chemo-radiotherapy

KW - Lung cancer

KW - Non-Small Cell Lung Cancer

KW - Tumour response

UR - http://www.scopus.com/inward/record.url?scp=85021839819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021839819&partnerID=8YFLogxK

U2 - 10.1007/s00259-017-3762-9

DO - 10.1007/s00259-017-3762-9

M3 - Review article

AN - SCOPUS:85021839819

VL - 44

SP - 1915

EP - 1927

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 11

ER -